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Osteosarcoma is the most frequent bone cancer in children and young adults. The outcome of patients with advanced
disease is dismal. Exploitation of tumor-immune cell interactions may provide novel therapeutic approaches.
CD70-CD27 interactions are important for the regulation of adaptive immunity. CD70 expression has been
reported in some solid cancers and implicated in tumor escape from immunosurveillance. In this study,
expression of CD70 and CD27 was analyzed in osteosarcoma cell lines and tumor specimens.
CD70 protein was expressed on most osteosarcoma cell lines (5/7) and patient-derived primary osteosarcoma
cultures (4/6) as measured by flow cytometry. In contrast, CD70 was detected on few Ewing sarcoma cell lines
(5/15) and was virtually absent from neuroblastoma (1/7) and rhabdomyosarcoma cell lines (0/5). CD70+ primary
cultures were derived from CD70+ osteosarcoma lesions. CD70 expression in osteosarcoma cryosections
was heterogeneous, restricted to tumor cells and not attributed to infiltrating CD3+ T cells as assessed by
immunohistochemistry/immunofluorescence. CD70 was detected in primary (1/5) but also recurrent (2/4) and
metastatic (1/3) tumors. CD27, the receptor for CD70, was neither detected on tumor cells nor on T cells in CD70+
or CD70− tumors, suggesting that CD70 on tumor cells is not involved in CD27-dependent tumor-immune cell
interactions in osteosarcoma. CD70 gene expression in diagnostic biopsies of osteosarcoma patients did not
correlate with the occurrence of metastasis and survival (n = 70).
Our data illustrate that CD70 is expressed in a subset of osteosarcoma patients. In patients with CD70+ tumors,
CD70 may represent a novel candidate for antibody-based targeted immunotherapy.
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Osteosarcoma is the most frequent bone cancer in chil-
dren and adolescents. Despite intensive chemotherapy,
patients with recurrent, metastatic and chemotherapy-
refractory osteosarcoma have a poor prognosis [1].
Osteosarcoma is frequently infiltrated by immune cells
such as macrophages and T cells [2,3]. Insight in tumor-
immune cell interactions may be instrumental to
develop novel treatment approaches like targeted im-
munotherapy. Aside from its role in adaptive immunity,
CD70 is expressed on certain solid tumors and reported
to be involved in tumor cell escape from immunosur-
veillance [4].* Correspondence: a.lankester@lumc.nl
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unless otherwise stated.CD70 is the natural ligand for the tumor necrosis fac-
tor (TNF) superfamily member CD27 and has originally
been described as a co-stimulatory molecule for B cell
and T cell activation [4,5]. Expression of CD70 in non-
malignant tissue is primarily confined to cells of the
hematopoietic system, yet mostly transient and tightly
regulated [4-7]. CD70 is absent from human and murine
naïve T cells, immature B cells and Natural Killer (NK)
cells, but induced by T cell and B cell receptor trigger-
ing, B cell transformation or NK cell activation by
interleukin-15 (IL-15) [4,8]. While absent from imma-
ture dendritic cells and neutrophils [9], CD70 expression
can be induced on myeloid and plasmacytoid dendritic
cells by e.g. toll-like receptor ligands in combination
with CD40 ligation [10,11]. Interaction of CD70 with its
receptor CD27 has originally been demonstrated to
enhance the expansion, interferon-γ (IFN-γ) and IL-2is is an Open Access article distributed under the terms of the Creative
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In addition, CD70 promotes survival of T cells responding
to low-affinity or low-dose antigens [14,15].
Accordingly, CD27 is expressed on naïve and central
memory CD4 and CD8 T cells as well as on thymocytes
[4,13]. In addition, CD27 is expressed on mature B cells
and CD70-CD27 signaling results in B cell expansion,
differentiation into plasma cells and IgG synthesis [5,16].
In innate immunity, CD70-CD27 interactions induce
proliferation and IFN-γ production (but not direct cyto-
toxicity) of NK cells in vitro and have been shown to
mediate NK cell-dependent tumor rejection in mice
[17,18]. CD27 is expressed on nearly all murine NK cells
[17]. On human NK cells CD27 is acquired during mat-
uration in lymphoid organs but down-regulated in ter-
minal maturation stages; in peripheral blood CD27+ NK
cells are functionally closely related to CD56bright NK
cells, whereas CD27− NK cells correspond to CD56dim
NK cells [8].
In addition to its function and transient expression
limited to innate and adaptive immune cells, abundant
CD70 expression has been documented in B cell malig-
nancies and renal cell carcinoma [6,19]. Hence, CD70-
CD27 interactions may possess additional functions in
cancer cells such as triggering tumor progression or
escape from immunosurveillance [20,21]. In addition,
CD70 on cancer cells is an attractive candidate for tar-
geted immunotherapy due to its restricted expression on
non-malignant cells.
In this study, we sought to determine the expression
of CD70 and CD27 in osteosarcoma as well as other




Tumor samples derived from biopsies (obtained at the
time of diagnosis, pre-chemotherapy) and resections of
primary, local recurrent and metastatic tumors (all post-
chemotherapy) from ten high-grade osteosarcoma patients
were freshly frozen in 2-methylbutane at the Department
of Pathology, Leiden University Medical Center.
From five of these patients, six primary osteosarcoma
cell cultures (cell passages ranging from 5 to 20) were
generated from the tumor material as previously described
[22]. An overview of tumor samples and primary cultures
as well as clinicopathological details of osteosarcoma pa-
tients is summarized in Table 1. Tumor specimens were
obtained and analyzed according to the ethical guidelines
of the national organization of scientific societies
(FEDERA, http://www.federa.org/gedragscodes-codes-
conduct-en). CD70 gene expression was analyzed from
a genome-wide gene profiling data base consisting of
diagnostic biopsies of 83 high-grade osteosarcomapatients as previously published [2] (accessible online
at http://hgserver1.amc.nl/cgi-bin/r2/main.cgi).
Cell lines
Established osteosarcoma cell lines HOS, HOS-143b,
OHS, OSA (SJSA-1), SAOS-2, U2-OS, ZK-58; and
Ewing sarcoma cell lines A673, CADO-ES, ET10, EW3,
IOR/BER, RD-ES, SK-ES-1, SK-N-MC, STA-ET1,
STA-ET2.1, TC71, VH64 and WE68 were obtained
from the EuroBoNeT cell line repository [23]. The Ewing
sarcoma cell line IOR/BER was kindly provided by K.
Scotlandi (Rizzoli Orthopaedic Institute, Bologna, Italy),
L1062 [22] and TC32 was obtained from the American
Type Culture Collection (TC32; Manassas, VA, USA).
TC71 cells were cultured in IMDM medium (Invitrogen,
Carlsbad, CA, USA). supplemented with 10% heat-
inactivated fetal calf serum (FSC), 100 U/ml penicillin and
100 ug/ml streptomycin (P&S) (all Invitrogen). All other
osteosarcoma and Ewing sarcoma cell lines as well as the
EBV-transformed B-LCL cell line 107 (established in our
laboratory) were cultured in RPMI-1640 medium (Invitro-
gen) supplemented with FCS and P&S. Ewing sarcoma cell
lines were grown in 0.1% gelatin coated tissue culture
flasks. The neuroblastoma cell lines SJNB8, SKNFI,
SKNBE, IMR32 (obtained from ATCC) were cultured in
DMEM Glutamax I medium (high glucose) supplemented
with FCS, P&S and 1% MEM-non-essential amino acids
(Invitrogen); UKF NBL1 and UKF NBL4 (kindly provided
by U. Koehl, Medical University of Hannover, Germany)
in IMDM medium with FCS and P&S; and CHP126 (ob-
tained from ATCC) in RPMI medium with FCS and P&S.
The rhabdomyosarcoma cell lines RD (obtained from
ATCC) and A204, TE671, RH30 and RH41 (obtained from
DSMZ, Braunschweig, Germany) were cultured in DMEM
medium with the above indicated supplements). All cell
lines were negative for mycoplasma infection.
CD70 protein expression by flow cytometry
The following mouse anti-human monoclonal antibodies
and mouse isotype control antibodies were used: CD70PE
(Ki-24) (BD Biosciences, Franklin Lakes, NJ, USA) (this
antibody produced comparable results to 2F2); CD70
2F2 (0.2 μg/ml; kindly provided by R.A.W. van Lier) and
IgG1 (0.2 μg/ml; R&D Systems, Minneapolis, MN, USA)
followed by the goat-anti mouse IgAPC secondary anti-
body (BD Biosciences). FACS measurements were per-
formed with the FACSCalibur (BD Biosciences) and
analyzed with the “BD Cell Quest ProTM” software (ver-
sion 5.2.1). On CD70+ high-passage established tumor
cell lines and low-passage primary tumor cultures, CD70
was homogenously expressed on the entire cell popula-
tion, enabling quantification of the fluorescence intensity
by the fold change of the geometric mean fluorescence
intensity (geoMFI) as indicated in the FACS histogram
Table 1 CD70 expression and clinicopathological details of patient material





















88 L1372 + n/a M 16 femur telangiectatic
363 L2792 - - M 17 femur osteoblastic
369 L2531 + + F 31 humerus fibroblastic
398 L2635 n/a + F 14 femur conventional
404 L2826 + + L3312 + + M 46 humerus conventional
407 L2857 n/a - M 9 tibia chondroblastic
1 L47 - n/a L1021 - n/a M 25 humerus n/a
6 L458 - n/a L1072 - n/a F 45 femur periosteal/juxtacortical
29 L1045 - n/a L1020 - n/a M 23 femur telangiectatic
47 L1046 - n/a L437 + n/a M 28 tibia n/a
n/a, not available; +, positive for CD70 expression; −, negative for CD70 expression.
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Figure 1 CD70 protein is abundantly expressed on osteosarcoma
cells. CD70 protein expression on the surface of (A) established
osteosarcoma cell lines and EBV-transformed B cell lymphoma
(EBV-B-LCL) cells and (B) patient-derived primary osteosarcoma
cultures (Table 1) was analyzed by flow cytometry. Fold change of
geoMFI of specific antibody stainings (bold solid line) compared
to geoMFI of isotype control (light shade) is indicated in the
representative FACS histogram plots. (C) CD70 protein expression
(fold change geoMFI, calculated as geoMFI of specific antibody
staining divided by geoMFI of the isotype control staining) on the
surface of established osteosarcoma cell lines and patient-derived
primary osteosarcoma cultures (geometric mean of three experiments),
and of established Ewing sarcoma (geometric mean of two experiments),
neuroblastoma (one experiment) and rhabdomyosarcoma (one
experiment) cell lines. In addition to the indicated osteosarcoma
cell lines, CD70 expression was detected on the Ewing sarcoma cell
lines CADO-ES, ET10, STA-ET2.1, VH64, WE68 and the neuroblastoma
line CHP126.
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ing the geoMFI of specific CD70 antibody staining by
the geoMFI of the isotype control staining.
CD70 gene expression
CD70 gene expression was analyzed from genome-wide
gene profiling data of osteosarcoma cell lines and pa-
tient’s tumor specimens as previously published [2].
Immunohistochemistry (IHC) and Immunofluorescence (IF)
Sections of 4 μm of representative tumor cryosections of
resection specimens (Table 1) and of B-cell lymphoma
control tissue were fixed in acetone at −20°C for 10 min
(for IHC: supplemented with 0.3% hydrogen peroxide
(Sigma-Aldrich, St. Louis, MO, USA) to inactivate endo-
geneous peroxidase), followed by incubation in 10% nor-
mal goat serum (Dako, Glostrup, Denmark) in PBS
buffer to block non-specific antibody binding.
Immunohistochemical expression of CD70 was assessed
using the mouse monoclonal anti-CD70 2 F2 (IgG1,
0.16 μg/ml) antibody followed by a polyclonal goat anti-
mouse/rabbit/rat IgG HRP-linker antibody conjugate
(Brightvision, DPVO-110HRP; Immunologic, Duiven, the
Netherlands) and DAB+ Substrate Chromogen System
(Dako) detection. All sections were examined with an
Olympus BX41 microscope and Cell^B acquisition soft-
ware (Olympus, Tokyo, Japan).
Immunofluorescent double-staining for CD3 and CD70
or CD3 and CD27 was performed with rabbit polyclonal
anti-human CD3 (2.4 μg/ml; Dako), CD70 2 F2 and
mouse monoclonal anti-human CD27 137B4 (IgG1, 1:200;
Novocastra, Leica Microsystems, Wetzlar, Germany)
followed by goat anti-rabbit Alexa 488 or goat anti-
mouse IgG1 Alexa 546 (1:300; Invitrogen, Carlsbad, CA,
USA). All sections were examined with a Leica DM5000
fluorescence microscope and LAS-AF acquisition pro-
gram (Leica, Solms, Germany).
Statistical analysis
Statistical analyses were performed with Graphpad Prism
version 5.04 (La Jolla, CA, USA). A P-value of <0.05 was
considered statistically significant.
Results
Osteosarcoma cell lines exhibit highest expression of
CD70 among pediatric solid cancer cell lines
CD70 membrane protein expression was investigated on
established osteosarcoma, Ewing sarcoma, neuroblast-
oma and rhabdomyosarcoma cell lines by flow cytome-
try. Expression of CD70 was detected on five out of
seven established osteosarcoma cell lines, on HOS,
HOS-143b, OSA, SAOS-2 and U2OS cells but not
OHS or ZK-58 cells (Figure 1, panel A). The cell line OSA
exhibited the highest expression of CD70 amongst all cell
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EBV-transformed B cells (EBV-B-LCL). In addition, four
out of six primary osteosarcoma cultures derived from five
osteosarcoma patients (Table 1) were positive for CD70
expression (Figure 1 panel B).
Noteworthy, of one patient (patient (p) 404) with cul-
tures from consecutive tumors, the culture derived from
the local recurrent tumor exhibited equally high CD70
expression as the culture derived from the primary
tumor of this patient. The level of CD70 expression on
the primary cultures was similar to the CD70 levels on
established osteosarcoma cell lines (Figure 1, panel C).
In contrast to CD70, its receptor CD27 was not detected
on any of the osteosarcoma cell lines (data not shown).
Moreover, CD70 was detected on few established Ewing
sarcoma cell lines (5/15) at lower intensities than on
osteosarcoma cell lines, while CD70 was hardly detected
on neuroblastoma (1/7) and rhabdomyosarcoma (0/5)
cell lines (Figure 1, panel C).
CD70+ primary osteosarcoma cultures are generated from
parental tumors containing CD70+ cells
Since in particular most osteosarcoma cell lines and
patient-derived primary osteosarcoma cultures exhibited
high CD70 protein expression, it was examined whether
CD70 was also expressed in (corresponding) osteosar-
coma tumors. Detection of CD70 by immunohistochem-
istry in large tissue microarrays is hampered by the lack
of commercially available anti-CD70 antibodies suitable
for paraffin-embedded tissue [24]. Instead, CD70 detec-
tion in individual frozen specimens is feasible as tested
and described for large diffuse B cell lymphoma tissue
(Figure 2) [19]. Therefore, we analyzed and compared
CD70 expression in available frozen specimens of our
collection of parental tumor specimens (n = 4) and cor-
responding primary cultures (Table 1). In addition, we
compared CD70 expression between recurrent/meta-
static lesions and primary tumors of the same patients
(n = 5) (Table 1).
Overall, CD70 expression tended to be more frequently
detected in recurrent (2/4) and metastatic (1/3) tumors
than in primary osteosarcoma tumors (1/5) (Table 1).
CD70 was heterogeneously expressed in the tumors in a
membranous pattern (Figure 2). Of the tumor-primary
culture combinations, parental tissue of L2531 (p363) ex-
hibited CD70-expressing cells in focal regions. The high
CD70 intensity of these cells was consistent with the
strong CD70 expression of the corresponding primary cul-
ture (Figure 1, panel B). Of L2792 (p369), CD70 was nei-
ther detected in the parental tissue nor on the primary
culture. Notably, of the one patient (p404) with tissue and
primary cultures from consecutive tumors, a majority of
cells of the local recurrent tumor (L3312) showed strong
CD70 expression, whereas only a few cells were weaklypositive in the primary tumor (L2826). Of this patient, the
primary cultures of both tumors were strongly positive for
CD70. In the residual four patients with combinations of
consecutive tumor specimens, one metastatic tumor
(L437, p47) contained CD70-expressing cells, while there
were no CD70-expressing cells detectable in the primary
tumor (L1046) of the same patient (Table 1).
Altogether, these results indicate that CD70 protein
can be expressed in primary, recurrent and metastatic
osteosarcoma lesions. Both high-passage cell lines and
low-passage primary tumor cultures showed homogenous
but different CD70 expression levels (or were negative)
which did not seem to change after further culturing (data
not shown). CD70 expression was only detected on
primary cultures if these were derived from a tumor speci-
men containing CD70+ cells, indicating that CD70 expres-
sion was not caused by in vitro cell culture. Thus because
cell lines were homogenously positive for CD70 even if
they grew from tumors in which not all cells expressed
CD70, these results suggest that CD70+ cells in the tumor
preferentially grow out to CD70+ primary patient-derived
cultures.
CD70 expression in osteosarcoma lesions is confined to
tumor cells and does not influence patient survival
To determine whether CD70 expression on tumor cells
would be associated with clinical outcome of patients
with osteosarcoma, we needed to investigate CD70 ex-
pression levels in a large cohort of patients with data on
follow-up. For this purpose, we wanted to use a public
dataset on gene (mRNA) expression of a large collection
of osteosarcoma biopsies.
Therefore, it was first investigated whether CD70
mRNA expression correlated with protein expression in
osteosarcoma cell lines. CD70 protein expression in
osteosarcoma cell lines indeed correlated with CD70
mRNA expression in these cells lines (r2 = 0.87, p < 0.002)
(Figure 3, panel A).
Next, CD70 gene expression was evaluated in diagnos-
tic biopsies of 83 osteosarcoma patients. A subset of pa-
tients (16/83) showed significantly higher CD70 gene
expression (above the upper 25 percentile as indicated)
(Figure 3, panel B). Of note, high CD70 gene expression
corresponded to strong CD70 protein staining in the
tumor biopsy as assessed for one patient (p88) with
available frozen tissue (L1372) (Figure 4, panel A; patient
(p88) indicated by * in Figure 3, panel A).
To investigate the association of CD70 expression by
tumor cells with clinical outcome, we first assessed
whether CD70 was expressed by tumor cells and not by
tumor-infiltrating T cells in this biopsy with high CD70
gene/protein expression (L1372, p88), since activated T
cells are known to express CD70 [9]. Strong immuno-
fluorescent staining for CD70 was confined to tumor
Figure 3 CD70 gene expression in osteosarcoma lesions does not influence survival. (A) CD70 protein expression (fold change geoMFI) on
the surface of established osteosarcoma cell lines, as analyzed by flow cytometry (Figure 1), was correlated with relative CD70 gene (mRNA)
expression of these cell lines, as analyzed by microarray. The regression coefficient (r2) between CD70 protein and CD70 gene expression was
0.87 (p = 0.002) as calculated by linear regression analysis. (B) CD70 relative gene (mRNA) expression in 83 biopsies of the primary tumor of 83
osteosarcoma patients depicted with the median and interquartile range. Elevated CD70 gene expression was evaluated as above the upper 25
percentile (16 patients, as indicated by the closed symbols). Asterix: biopsy L1372 of osteosarcoma patient 88 with high CD70 gene expression
and available frozen tissue for immunohistochemical and immunofluorescent protein stainings as depicted in Figure 4. (C) Metastasis-free survival
of osteosarcoma patients during ten years of follow-up comparing survival with high and low CD70 gene expression. Of the 83 patients (n = 16:
CD70high gene expression and n = 67: CD70low gene expression) depicted in panel B, 13 patients with metastasis at time of diagnosis were
excluded, resulting in the inclusion of 70 patients (n = 15: CD70high, and n = 55: CD70low) for this analysis. Mantel-Cox univariate survival analysis
resulted in a log-rank χ2 score of 0.29 (p = 0.59).
Figure 2 Heterogeneous CD70 protein expression in osteosarcoma lesions. Immunohistochemical CD70 protein staining in one specimen of
diffuse large B cell lymphoma and four osteosarcoma specimens of three osteosarcoma patients (L2531 of p363; L2792 of p369; L2826 and L3312 of
p404) (Table 1) Brown-colored CD70 staining patterns and counterstaining with Mayer’s hematoxylin are displayed at a 40-fold magnification.
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Figure 4 CD70 protein expression in osteosarcoma lesions is expressed on tumor cells and not on tumor-infiltrating T cells.
Immunohistochemical stainings for CD70 and immunofluorescent double stainings for CD70 (red) and CD3 (green) as well as CD27 (red) and
CD3 (green) (cell nuclei in blue) was assessed in sequential specimens of the osteosarcoma biopsy L1372 (p88) with high CD70 gene expression
as indicated by the asterix in Figure 3, panel A.
Pahl et al. Cancer Cell International  (2015) 15:31 Page 7 of 9cells and did not co-localize with the T cell marker CD3
(Figure 4, panel B). In contrast to CD70, its receptor
CD27 was detected neither in CD70+ nor CD70− osteo-
sarcoma lesions and was not expressed by infiltrating T
cells (Figure 4, panel C and data not shown).
Next, it was determined whether higher CD70 gene
expression was correlated with the occurrence of metas-
tasis, which is the most important parameter for survival
of osteosarcoma patients. Thirteen patients presenting
with metastasis at time of diagnosis were excluded from
this analysis. In the remaining 70 patients, the occur-
rence of overt metastasis (metastasis-free survival) dur-
ing ten years of follow-up was not statistically different
between patients with high or low CD70 gene expression
(log-rank χ2 = 0.29, p = 0.59) (Figure 3, panel C). There
was no association between CD70 gene expression and a
specific tumor location or histological subtype (data not
shown).
In conclusion, high CD70 expression in osteosarcoma
tumors is not associated with better or worse metastasis-
free survival.
Discussion
We demonstrate that CD70 is expressed on the majority
of osteosarcoma cell lines as well as patient-derived
osteosarcoma cultures which were derived from CD70+
tumor tissue. CD70 expression in tumor lesions was het-
erogeneous and restricted to tumor cells and not attrib-
uted to infiltrating T cells. CD70 gene expression in
diagnostic biopsies was significantly higher in a subset of
osteosarcoma patients but this difference was not corre-
lated with metastasis-free survival.
Among pediatric bone and soft tissue cancers, we
found that CD70 is preferentially expressed on osteosar-
coma cells (9/13). CD70 was detected on few Ewing
sarcoma cells (5/15) and was virtually absent from
neuroblastoma and rhabdomyosarcoma cells, indicating
that CD70 expression is restricted to certain cancertypes like renal cell carcinoma and osteosarcoma and to
a lesser extent brain cancers, larynx or pharynx cancer,
melanoma, pancreatic cancer, ovarian carcinoma and
Ewing sarcoma [6,7,20,24-26]. Among the osteosarcoma
specimens we tested, CD70 expression was heteroge-
neous between patients as well as within the tumor. In a
larger cohort of 83 osteosarcoma patients, a subset of
tumor biopsies (19%) showed significantly higher CD70
gene expression.
This raises the question whether CD70 exerts a bio-
logical function in certain cancer types or certain can-
cer cells. In some tumor-transformed B cells, CD70
(downstream) signaling may affect proliferation and
apoptosis [19,20,27]. In spite of this, in most studies,
biological effects of CD70 have been demonstrated to
be mediated by interactions of CD70 with its receptor
CD27, which can have a dual role in regulating anti-
tumor adaptive immune responses. Acute challenge
with CD70+ tumor cells was shown to induce anti-tumor
T cell-mediated immunity [18]. Similarly, CD70-CD27 in-
teractions promote anti-virus and anti-tumor T cell re-
sponses [28,29]. On the contrary, co-culture of CD70+
tumor cells and CD27+ immune cells was shown to inhibit
alloreactive T cell proliferation and induce T cell apoptosis
[20,30]. Similarly, continuous CD70-CD27 co-stimulation
in CD70-transgenic mice or in mice chronically infected
with mouse choriomeningitis virus exhausts the naïve T
cell pool in favor of effector memory T cells that ultim-
ately results in T cell dysfunction unless relieved from the
CD70-CD27 brake [28,31]. In line with the latter observa-
tions, CD70+ tumor cells in renal cell carcinoma and B
cell lymphoma may promote depletion of naïve CD27+ T
cells and induce regulatory T cells in the tumor, respect-
ively [32,33].
Hence, during a persistent tumor-immune cell inter-
action, CD70 expression on tumor cells may support
tumor escape from immunosurveillance and thus be
disadvantageous for patient outcome. However, to our
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on tumor cells with patient survival has not been de-
scribed in these human tumors [26]. In our cohort of
osteosarcoma patients, CD70 gene expression at the
time of diagnosis did not correlate with metastasis-free
survival, suggesting that at least in osteosarcoma, CD70
expression does not promote tumor progression. More-
over, CD27 was neither detected on tumor cells nor on
infiltrating T cells in osteosarcoma lesions, suggesting
that CD70 on tumor cells is not involved in CD27-
dependent tumor-immune cell interactions. In spite of
the ambiguous role of CD70 in cancer development and
progression, its substantial expression in certain cancers
would make CD70 an attractive immunotherapeutic tar-
get. This is supported by the highly restricted expression
of CD70 on immune cells and its virtual absence in
normal non-hematopoietic tissue, which may limit side-
effects of CD70 targeted treatment [6,24]. In this per-
spective, chimeric antigen receptor T cells (CD27-CD3ζ)
have been reported to kill CD70+ tumor cells and medi-
ate tumor regression in mice [34]. Moreover, therapeutic
chimeric and humanized anti-CD70 antibodies are
currently developed. In preclinical studies, anti-CD70
antibodies demonstrated indirect anti-tumor efficacy
mediated by NK cells and macrophages involving
antibody-dependent cellular cytotoxicity and tumor cell
phagocytosis, respectively, as we have similarly recently
reported using the clinically-approved anti-epidermal
growth factor receptor antibody cetuximab [22,35]. In
addition, if conjugated to cytotoxic drugs anti-CD70
antibodies can mediate direct anti-tumor effects [6,24].
Since we had no access to chimeric or humanized
anti-CD70 antibodies, we could not test direct or in-
direct cytotoxicity against CD70-expressing osteosar-
coma cells. Altogether, in osteosarcoma patients with
CD70-postive tumors, CD70 may constitute a tumor
antigen for novel targeted immunotherapy.
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